03.05.2010 • NewsLyondellBasellbankruptcy

Lyondell Chemical Emerges from Bankruptcy

Lyondell Chemical  said on Friday that it has exited bankruptcy after a 16-month process during which its debt load was reduced to about $5 billion from $24 billion.

The company, which went bankrupt last January after a drop in business due to the economic downturn left it unable to make debt payments, was able to make the move through financial backing from two private equity firms and industrial holding company Access Industries.

Access, owned by financier Len Blavatnik, had taken Lyondell private in 2007. He has bought back into the new company through a $2.8 billion rights offering and will own a small stake alongside Apollo Management and Ares Management.

Lyondell also said it raised $3.25 billion of first priority debt. The new company, LyondellBasell Industries NV based in the Netherlands, said it expects to begin trading on the New York Stock Exchange by the third quarter of this year. LyondellBasell said it has $5.2 billion in net consolidated debt and about $3 billion in liquid assets.

The move comes after the company fended off a takeover attempt by India's Reliance Industries earlier this year. It also settled hundreds of environmental claims.

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.